The Prostate · 2007 · 41 citations · 63 references
MedicineOncologyPharmacologyApoptosisMolecular OncologySignal TransductionApoptosis In CancerApoptosis ResistanceApoptotic SignalingCancer Cell SignalingProstate CancerTherapeutic ResistanceApoptotic ResponseCancer Cell Survival SignalingCell Survival AssaysMitochondrial Membrane Potential CollapseProstatic AdenocarcinomaSphingosine 1-Phosphate SignalingSphingosine-1-phosphate SignalingTherapeutic Resistance Mechanisms
BACKGROUND: Elevated BCL-2 is one mechanism of therapeutic resistance in prostate cancer (PC), and new approaches are needed to overcome such resistance. METHODS: We evaluated the effects of BCL-2 over-expression in human prostatic adenocarcinoma cells on their susceptibility to sphingolipids (SLs) and to the sphingosine kinase (SpK) inhibitor, SKI II. RESULTS: In survival assays, no significant differences were observed in the responses to sphingosine or ceramide among parental PC-3 cells lacking detectable BCL-2 and BCL-2 over-expressing PC-3 transfectants; similarly, the responses to dimethyl-sphingosine (DMSP) of parental LNCaP cells and a BCL-2 over-expressing LNCaP transfectant were equivalent. SKI II induced protracted, BCL-2-independent survival loss in both PC-3 and LNCaP parental/transfectant pairs; in contrast, DMSP induced rapid cell shrinkage, caspase activation and caspase-dependent DNA fragmentation. DMSP-induced DNA fragmentation and loss of mitochondrial membrane potential were equivalent in BCL-2 transfectants and parental PC-3 cells and were not associated with BCL-2 downregulation. DMSP-mediated cytotoxicity was not associated with the enhanced production of reactive oxygen intermediates. SL analyses of parental and transfectant PC-3 cells did not reveal increased levels of sphingosine-1-phosphate in the BCL-2 transfectants; further, there only a modest early shift, corresponding to apoptotic onset, in pro- versus anti-apoptotic SLs in response to DMSP treatment. CONCLUSIONS: Thus, in contrast to the inhibitory effects of BCL-2 on apoptosis induced by various agents in tumor cells, SKI II and selected pro-apoptotic SLs appear atypical in their independence from such inhibition, and may have merits as new candidates for treatment of AI PC.
63
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations
Discovery and evaluation of inhibitors of human sphingosine kinase.
Kevin J. French, Randy S. Schrecengost, Brian D. Lee et al. · PubMed · 2003 · 600 citations
Medicine, Oncology, Pharmacology +10